Aripiprazole
Heterocyclic Compound
Drugmakers mostly post higher profits, muted salesIt had sales of $5.49 billion, up nearly 5 percent. Abilify, Orencia for rheumatoid arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude all had double-digit sales increases. Blood thinner Plavix, the world's No. 2 drug, had... In this article: Merck & Co., Schering-Plough Corp, Revenue, Bristol-Myers, Novartis AG, Januvia, Allergy, U.S., Recession, and Tax |
-
Centre Daily Times | October 22, 2009
Bristol-Myers posts higher 3Q sales, lower profit
Several Bristol-Myers drugs had double-digit sales jumps. Those included Abilify, Orencia for rheumatoid arthritis, leukemia drug Sprycel and hepatitis B drug Baraclude. The company also launched its newest drug, Onglyza for diabetes,...
In this article: Bristol-Myers, Revenue, Abilify, Bipolar disorder, Baraclude, Sprycel, Plavix, Reyataz, Leukemia, and Orencia
-
Seeking Alpha | October 22, 2009
Bristol-Myers Squibb Q3: Beats by a Penny
...up 8%, HIV medication Sustiva at $315 million, up 7% and hepatitis B drug Baraclude at $191 million, up 33%, Schizophrenia drug Abilify came in at $653 million, up 16%, rheumatoid arthritis drug Orencia was at $162 million, up 36% and...
In this article: Bristol-Myers Squibb, Revenue, Plavix, AstraZeneca plc, Bristol, Ipilimumab, LLY, Sanofi-Aventis, and Baraclude
-
www.leukemia-web.org
FDA Safety Labeling Changes: Ellence, Abilify, Kaletra
... in risk of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) ... risk of developing leukemia; use of aripiprazole HCl in elderly patients ...
-
www.docguide.com
News - FDA Approves Aripiprazole as Adjunctive to Lithium or ...
FDA Approves Aripiprazole as Adjunctive to Lithium or Valproate in Adults With Bipolar 1 Disorder ... Aripiprazole has been approved as monotherapy for the ...
-
News - Aripiprazole Shows Long-Term Treatment Efficacy in ...
Aripiprazole Shows Long-Term Treatment Efficacy in Bipolar Disorder: Presented at ECNP ... FDA Approves Aripiprazole to Treat Irritability Associated With ...
-
www.medicinenet.com
ARIPIPRAZOLE - ORAL (Abilify) side effects, medical uses, and ...
Read more about the prescription drug ARIPIPRAZOLE - ORAL. ... Chronic Myelogenous Leukemia. Oseltamivir (Tamiflu) H1N1. H1N1 Swine Flu and Pets ...
-
www.ehow.com
Side Effects of Aripiprazole | eHow.com
Aripiprazole, which is more commonly known as Abilify, is an ... Leukemia Treatments. Menopause Treatments. Skin Cancer Treatments. Weight Gain Treatments ...
-
www.dovepress.com
Aripiprazole: the evidence of its therapeutic impact in ...
Aripiprazole: the evidence of its therapeutic impact in schizophrenia William Winlow, Louise Profit, ... Tipifarnib in the treatment of acute myeloid leukemia ...
-
www.ecureme.com
Abilify(Aripiprazole)
Abilify(Aripiprazole) Central nervous system agent. Antipsychotic agent. Schizophrenia ... A: Studies in pregnant women failed to show a risk to the fetus in the first ...
Trends
Loading...
More on Aripiprazole
Description from Wikipedia:
Aripiprazole (ay-ree-PIP-ray-zole) (sold as Abilify) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, as well as treatment of depression. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.
Explore everything named Aripiprazole...
